Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response by Burgess, Joshua T et al.
OPEN
Activation and cleavage of SASH1 by caspase-3
mediates an apoptotic response
Joshua T Burgess1, Emma Bolderson*,1,2, Mark N Adams1, Anne-Marie Baird1, Shu-Dong Zhang3,4, Kathy A Gately5, Kazuo Umezawa6,
Kenneth J O’Byrne1,2 and Derek J Richard*,1,2
Apoptosis is a highly regulated cellular process that functions to remove undesired cells frommulticellular organisms. This pathway
is often disrupted in cancer, providing tumours with a mechanism to avoid cell death and promote growth and survival. The putative
tumour suppressor, SASH1 (SAM and SH3 domain containing protein 1), has been previously implicated in the regulation of
apoptosis; however, the molecular role of SASH1 in this process is still unclear. In this study, we demonstrate that SASH1 is cleaved
by caspase-3 following UVC-induced apoptosis. Proteolysis of SASH1 enables the C-terminal fragment to translocate from the
cytoplasm to the nucleus where it associates with chromatin. The overexpression of wild-type SASH1 or a cleaved form of SASH1
representing amino acids 231–1247 leads to an increase in apoptosis. Conversely, mutation of the SASH1 cleavage site inhibits
nuclear translocation and prevents the initiation of apoptosis. SASH1 cleavage is also required for the efficient translocation of the
transcription factor nuclear factor-κB (NF-κB) to the nucleus. The use of the NF-κB inhibitor DHMEQ demonstrated that the effect of
SASH1 on apoptosis was dependent on NF-κB, indicating a codependence between SASH1 and NF-κB for this process.
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Apoptosis is an essential cellular program designed to remove
unwanted cells from organs and tissues. Apoptosis is also a
crucial process for normal human embryonic development.
Apoptotic pathways can be initiated by several mechanisms
including the induction of excessive genome instability. Once
activated apoptosis results in a coordinated and controlled
process that ultimately leads to cell death. Disruption of the
apoptotic process contributes to the development of many
human diseases including cancer and immune disorders.1,2
Key modulators of the apoptotic response are the caspase
family of cysteine proteases. Caspase-9 activation is an early
apoptotic event occurring after the release of cytochrome C
from the mitochondria. Once activated caspase-9 cleaves
downstream caspases resulting in the progression of the
apoptotic response.3 Of this caspase family, caspase-3,
caspase-6 and caspase-7 are the major effector proteases in
apoptosis.3,4 The proteolytic activity of the caspase family is
tightly regulated, and upon activation, these proteases cleave
numerous substrates at specific sites. In general, caspase
substrates become inactivated upon cleavage; however, a
subset become activated and contribute to apoptosis.5 To
understand completely the role of caspases in apoptosis, it is
essential to identify their downstream targets.
SAM and SH3 domain containing 1 (SASH1) is a putative
tumour suppressor gene. In breast, lung, thyroid and color-
ectal cancers, SASH1 mRNA levels were found to be
significantly reduced, compared with adjacent normal
tissue.6,7 Low SASH1 levels also correlate with aggressive
tumour growth, metastasis and poor prognosis.8,9 Methylation
of the SASH1 promoter (particularly CpG_26.27 and
CpG_54.55) correlates with SASH1 repression in breast
cancer.10 The exact functions of SASH1 in normal tissues
and in cancer are still unclear, but it is known to be localised to
the nucleus and its SAM and SH3 domains imply signalling,
adaptor and/or molecular scaffold functions.11,12 The associa-
tion of SASH1 with apoptosis has been reported in several
studies.7,13–15 For example, SASH1 depletion has been
described to increase significantly cellular viability, prolifera-
tion and migration in A549 cells, whereas overexpression of
SASH1 resulted in a significant increase in apoptosis.7
SASH1 overexpression has also been shown to affect
apoptotic proteins including an increase in caspase-3
expression.13 Given the link of SASH1 with cancer, it is
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important to characterise the role of SASH1 in apoptosis to
use SASH1 as a biomarker or therapeutic target.
NF-κB has been described to both inhibit and promote
apoptosis. NF-κB is a transcription factor composed of five
members: RelA (p65), RelB, c-Rel, NF-κB1 (p105) and
NF-κB2 (p100), all of which contain a rel homology domain
that is responsible for their DNA-binding and transcription
regulatory functions.16,17 The NF-κB pathway is involved in
diverse pathways including regulation of cell differentiation,
proliferation and survival, as well as inflammatory
cytokines.18–20With such varied functions, the NF-κB pathway
is under tight regulation with positive and negative regulatory
elements.21 NF-κB is regulated by binding to the IkB protein,
with this sequestering NF-κB to the cytoplasm. Activation of
NF-κB occurs when IkB is phosphorylated by the IkB kinase,
targeting IkB for proteasome degradation. This releases
NF-κB, allowing it to translocate to the nucleus.22 The
NF-κB-associated inhibitors of apoptosis c-IAP1 (cellular
inhibitor of apoptosis protein-1), c-IAP2 and XIAP (X-linked
inhibitor of apoptosis protein) suppress apoptosis through
direct inhibition of effector caspases, whereas the members of
the B-cell CLL/lymphoma 2 (bcl-2) family activate the
proapoptotic members.23–25 Bcl-2 functionswithin cell survival
by controlling the mitochondrial membrane permeability
through the inhibition of the proapoptotic factors, BAX
(BCL2-associated X protein) and BAK (BCL2 antagonist/
killer 1). The increase in BAX and BAK from accumulative
cellular stress as well as a decrease in bcl-2 levels results in
mitochondrial membrane permeability releasing cytochrome c
and activating APAF1 (apoptotic protease-activating factor 1)-
induced caspase-9 cleavage and the apoptotic response.
In this study, we further characterise the mechanistic role of
SASH1 in apoptosis. We demonstrate that depletion of
SASH1 by siRNA results in resistance to UVC-induced
apoptosis. Furthermore, we show that following induction of
apoptosis, cytoplasmic SASH1 is cleaved by caspase-3 and
this cleaved C-terminal fragment of SASH1 is translocated to
the nucleus. Loss of this site prevents caspase-3 cleavage and
results in the loss of nuclear SASH1. Further, we show that
SASH1-mediated induction of apoptosis occurs through an
NF-κB-dependent mechanism. Interestingly, NF-κB transloca-
tion to the nucleus following the initiation of apoptosis is at
least in part dependent on SASH1.
Results
SASH1 has previously been reported to participate in the
regulation of apoptosis.7,13–15 To explore the molecular
mechanism through which SASH1 functions in apoptosis,
we initially depleted SASH1 in HeLa cells using esiRNA
(endoribonuclease-prepared siRNA) and then irradiated these
cells with 30 mJ/cm2 UVC to induce apoptosis through a
caspase-3-dependent pathway. Cell lysates were analysed by
immunoblot for caspase-9 activation via its autocleavage. This
demonstrated that depletion of SASH1 reduced caspase-9
cleavage, suggesting that SASH1 has a role in the progres-
sion of apoptotic pathways (Figure 1a). To further explore if
apoptosis had been suppressed in the absence of SASH1, we
depleted SASH1 from HeLa cells using esiRNA and analysed
the presence of surface-exposed Annexin V via FACS.
Following UVC treatment, there were significantly less
Annexin V-positive cells present in the SASH1-depleted cells
as compared with the mock-treated cells, indicating that
apoptosis was suppressed in the absence of SASH1
(Figure 1b). Consistently, depletion of SASH1 from A549 lung
cancer cells (Supplementary Figure 1A) suppressed apopto-
sis (Supplementary Figure 1B), whereas the use of an
alternative siRNA targeting SASH1 (GenePharma, Shanghai,
China; Supplementary Figure 2A) also significantly sup-
pressed apoptosis (Supplementary Figure 2B). The treatment
of SASH1-depleted cells with staurosporine (Supplementary
Figure 3A), which induces apoptosis by inhibiting protein
kinase activity, demonstrated that the SASH1-depleted cells
were more resistant to the staurosporine apoptotic stimuli.
The overexpression of SASH1 has been described to
induce apoptosis.7,13–15 To confirm this, we ectopically over-
expressed SASH1 in HeLa cells and measured the cleavage
of poly (ADP-ribose) polymerase (PARP1), caspase-3 and
caspase-9 by immunoblot. This showed that overexpression
of SASH1 increased the cleavage of proteins involved in
apoptotic pathways before and after UVC treatment. This
confirmed the observations from previous studies that SASH1
overexpression induces apoptosis (Figure 2a). While over-
expression of SASH1 in A549 cells did not affect PARP1
cleavage, overexpression induced a marked increase in
caspase-9 cleavage (Supplementary Figure 4A). Overexpres-
sion of SASH1 significantly increased apoptosis in A549 cells
(Supplementary Figure 4B).
Interestingly, following induction of apoptosis in HeLa cells
via UVC exposure or treatment with the staurosporine, a lower
molecular weight antigenic band was observed on an
immunoblot incubated with SASH1 antibodies (Figure 2b
and Supplementary Figure 5). While the predicted molecular
weight of full-length SASH1 is 170 kDa, the UVC-induced
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Figure 1 SASH1-depleted cells are resistant to apoptosis. (a) Immunoblot of
control or SASH1-depleted (knockdown (KD)) HeLa cells 3 or 6 h following ultraviolet
light C (UVC) exposure (30 mJ/cm2) probed for the apoptotic marker cleaved
caspase-9 and β-actin as a loading control. Less cleaved caspase-9 was observed in
SASH1-depleted cells, indicating a reduced apoptotic response to UVC. (b)
Quantification of Annexin PI profiles of HeLa cells, control or KD. Cells were harvested
(3 h after 30 mJ/cm2) and stained with Annexin V 488 and PI and analysed on the
Gallios flow cytometer. Data shown are the means± S.D. from five independent
experiments. Statistical analysis was performed with Student's T-test with
***Po0.0001
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smaller SASH1 product was observed at ~ 150 kDa. To further
investigate whether the 150 kDa SASH1 band is functional,
we performed subcellular fractionation of HeLa cells. Immu-
noblotting demonstrated that while the 170 kDa full-length
SASH1 was predominantly cytoplasmic, the 150 kDa form
was predominantly nuclear (Figure 2c). Sigma HPA029947
anti-SASH1 antibody is raised against amino acid (744–838)
located approximately in the middle of the SASH1 sequence;
therefore, the detection of SASH1 following small cleavage
events is possible. We next examined if the localisation of
SASH1 to the nucleus was stimulated by UVC. HeLa cells
were irradiated with UVC and fixed at time points after
treatment. Cells were pre-extracted with a detergent buffer
before fixation to remove non-chromatin-bound proteins,26,27
and this consistent with our subcellular fractionations indi-
cated that SASH1 localised to detergent-resistant chromatin
structures following UVC irradiation (Figure 2d). Lower bands
are also detected with the SASH1 antibody as well as the Flag
antibody, which may indicate alternative cleavage events of
SASH1 (Supplementary Figure 6A).
To explore if the 150 kDa form of SASH1 is the result of a
proteolytic cleavage event, we ectopically expressed SASH1
in U2OS cells either with a N- or C-terminal flag tag fusion
without additional apoptotic stimuli. Cell lysateswere analysed
by immunoblot using an anti-flag antibody. The 150 kDa form
of SASH1 was not produced from the N-terminal-tagged
SASH1, whereas a prominent 150 kDa band could be
observed in the lysates from cells expressing C-terminal-
tagged SASH1 (Figure 3a). This indicated that the 150 kDa
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Figure 2 SASH1 overexpression induces apoptosis. (a) HeLa cells were
transfected with Flag-SASH1 (OE= overexpressed) and irradiated with ultraviolet
light C (UVC) 3 h to induce apoptosis (10–50 mJ/cm2). Quantification of PARP1,
cleaved caspase-3 and cleaved caspase-9 levels indicated below blots wasperformed
with ImageJ (University of Wisconsin, Madison, USA). Statistical analysis was
performed with Student's T-test with *Po0.01 and **Po0.001. (b) Immunoblot of
UVC-treated HeLa cells (3 h after 30 mJ/cm2) indicating cleavage of SASH1 from 170
to 150 kDa. PARP1, caspase-3 and caspase-9 antibodies were also used as markers
of apoptosis. (c) HeLa cells were subjected to subcellular fractionation and
immunoblotted. The immunoblot was incubated with SASH1, histone H3 as a
chromatin marker and heat-shock protein 90 (HSP90) antibodies as a cytoplasmic
marker (ThermoScientific Subcellular Fractionation Kit). (d) Representative images
from immunofluorescence using SASH1 antibodies in HeLa cells following UVC
(50 mJ/cm2). DAPI (4',6-diamidino-2-phenylindole) was used to stain the nucleus of
the cells
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Figure 3 SASH1 is cleaved by caspase-3 at D230. (a) Immunoblot of U2OS cells
overexpressing N- or C-terminal Flag-tagged SASH1. (b) Coomassie-stained sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel containing
immunoprecipitation of C-terminal Flag-tagged SASH1. (c) Schematic diagram of
SASH1 protein domains indicating cleavage site and N-terminal sequencing of amino
acids (GSYPTF), which are preceded by a caspase-3 recognition site (DXXD).
(d) SASH1 was immunoprecipitated from SASH1-Flag stably expressing U2OS cells
using M2 Flag beads, followed by induction of apoptosis by UVC (50 mJ/cm2, 3 h)
with cells pre-treated (30 min) with caspase-3 inhibitor Z-VAD-FMK (20 μM).
(e) SASH1 is cleaved by recombinant caspase-3. SASH1 was immunoprecipitated
from U2OS cells as per (d) and incubated with recombinant caspase-3 (2 U, 16 h).
(f) Ectopically expressed 230E mutant SASH1 is not cleaved following UVC
exposure. HeLa cells overexpressing wild-type or D230E were treated with UVC
(50 mJ/cm2, 3 h). Cell extracts were immunoblotted and incubated with the indicated
antibodies. (g) SASH1 230E mutant is not cleaved by recombinant caspase-3. Cell
extracts taken from HeLa cells overexpressing wild-type and 230E SASH1 were
incubated with recombinant caspase-3 (2 U, 16 h)
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lower molecular weight fragment of SASH1 was produced as
the result of a cleavage event proximal to the N terminus.
To identify the exact site of SASH1 cleavage, we performed
N-terminal sequencing. C-terminal Flag-tagged SASH1 was
ectopically expressed in HeLa cells. The expressed protein
was immunoprecipitated from cell lysates using M2 resin
(Sigma-Aldrich, Castle Hill, NSW, Australia), transferred onto
polyvinylidene fluoride (PVDF) and stained with Coomassie
blue G250 (Figure 3b). The peptide corresponding to the
cleaved N-terminal fragment of SASH1 was then excised and
subjected to N-terminal sequencing. The cleavage site was
identified as D*G corresponding to amino acids 230 and 231
(Figure 3c). This represented a putative caspase-3 recognition
site (DWPD) and was located between the trypan PARP and
SLY domains of SASH1 (Figure 3c). To confirm whether
SASH1 is cleaved by caspase-dependent proteolysis, we
exposed U2OS cells stably overexpressing SASH1 to UVC
and treated the cells with or without the pancaspase inhibitor
Z-VAD-FMK and immunoblotted for SASH1. Consistent with
the involvement of a caspase protease, the 150 kDa form of
SASH1was not detected in lysates from cells exposed to UVC
and treated with Z-VAD-FMK, suggesting that caspase
inhibition prevents SASH1 cleavage (Figure 3d). To determine
if SASH1 is cleaved by caspase-3 and not a downstream
protease, we incubated immunoprecipitated (C-terminal Flag
tag) SASH1 with recombinant purified caspase-3. Immunoblot
analysis of the reaction indicated the presence of the cleaved
150 kDa SASH1 band after incubation with recombinant
caspase-3 (Figure 3e). This revealed that SASH1 could be
cleaved by caspase-3 in a purified reconstituted assay.
Further, the overexpression of the C-terminal Flag-tagged
SASH1 D230E mutant in HeLa cells inhibited the cleavage of
SASH1 following UVC irradiation, confirming that the aspartic
acid at amino acid 230 is essential for the caspase-3 cleavage
(Figure 3f). Taken together, this supports the possibility that
the cleavage of this site is by a caspase protease. To confirm
the site of cleavage, we next incubated immunoprecipitated
wild-type SASH1 and the SASH1 caspase-3 cleavage site
mutant D230E with recombinant caspase-3. Immunoblot
analysis indicated that the D230E mutant protein could not
be cleaved by recombinant caspase-3, confirming that the site
of cleavage is D230 (Figure 3g).
We next sought to determine if the cleavage of SASH1 is
required for the apoptotic function of SASH1. To explore this
possibility, the SASH1 N- and C-terminal fragments were
cloned and ectopically expressed in HeLa cells (Figure 4a).
Transduced HeLa cells were analysed for necrosis, early
apoptosis and late apoptosis in the absence of UVC. This
indicated that overexpression of SASH1 in HeLa cells
increased baseline apoptosis as expected, whereas over-
expression of the uncleavable D230E mutant showed no
increase in apoptosis (Figure 4b). Overexpression of the
C-terminal SASH1 fragment was observed to act in the same
manner as the full-length SASH1, suggesting that this
fragment (231–1247) was enough to prime cells for apoptosis
(Figure 4b). Interestingly, these data demonstrate that over-
expression of SASH1 or the 231–1247 fragment of SASH1
initiates apoptosis in cells in the absence of an additional
apoptotic stimulus.
Previous studies have shown a role for SASH1 in regulating
NF-κB activity.28 SASH1 was shown to independently bind IκB
kinase α and IκB kinase β, which resulted in the promotion of
NF-κB signalling. NF-κB also has a role in apoptosis,
functioning to regulate the expression of anti- and proapoptotic
factors.21,24 In light of the above, we next sought to determine
whether SASH1 influenced apoptosis through an NF-κB-
dependent mechanism. HeLa cells were depleted of SASH1
or mock treated and irradiated with UVC to induce apoptosis.
While normal NF-κB phosphorylation and accumulation was
observed in the control siRNA-treated cells, there was a delay
in NF-κB activation in SASH1-depleted cells, suggesting that
SASH1 is required for efficient activation of NF-κB (Figure 5a).
After induction of apoptosis NF-κB is translocated to the
nucleus. We next investigated the nuclear translocation of
NF-κB in cells transfected with control or SASH1 siRNA via
immunofluorescence. Depletion of SASH1 significantly dis-
rupted the translocation of NF-κB to the nucleus (Figure 5b),
suggesting that SASH1 is required for NF-κB recruitment to
the nucleus to promote apoptosis. To explore if cleaved
SASH1 was required for NF-κB translocation, we expressed
recombinant SASH1, D230E SASH1 and the SASH1 C-term-
inal fragment 231–1247 in HeLa cells exposed to UVC. It was
observed that the expression of full-length SASH1 (WT) and
231–1247 SASH1 led to an increase in nuclear NF-κB
regardless of the presence of endogenous SASH1 protein.
Therefore, NF-κB activation was dependent on D230 of
SASH1 and expression of the C-terminal fragment alone
was enough to activate NF-κB and stimulate its translocation
to the nucleus (Figure 5c). The localisation of SASH1 to the
nucleus was also shown to be dependent on SASH1
cleavage, with D230E having significantly less nuclear
staining relative to cytoplasmic staining while the nuclear
levels of 1–230 and 231–1247 SASH1 were elevated
(Supplementary Figure 7A). In addition, SASH1 230E did
not display a significant increase in SASH1 nuclear levels
following UVC, in contrast to the increase in SASH1 WT or
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Figure 4 Overexpression of SASH1 amino acids 231–1247 induces apoptosis.
(a) Immunoblot indicating the overexpression of SASH1 fragments from the cells
used in (b). (b) Annexin V and PI staining of HeLa cells 48 h following overexpression
of control (empty PCMV6 vector), SASH1 WT, SASH1 230E, SASH1 1–230 or
SASH1 231–1247 fragments. Fluorescence of cells was measured using a Gallios
flow cytometer (Beckman) and was quantified using the Kaluza software (Beckman).
The percentage of live and apoptotic cells is shown. The data represent the average
and S.D. of three independent experiments. Unpaired T-test with *Po0.05 and
**Po0.005
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SASH1 mutant 231–1247 nuclear levels (Supplementary
Figure 7B).
Although NF-κB required SASH1 for efficient activation and
translocation to the nucleus, we next investigated whether the
SASH1-induced apoptosis was dependent on NF-κB. HeLa
cells were ectopically transfected with empty vector GFP
(green fluorescent protein) or SASH1-GFP and treated with
escalating doses of the NF-κB inhibitor DHMEQ.29,30 Apop-
tosis induced by the overexpression of SASH1-GFP was
significantly reduced in a dose-dependent manner by inhibi-
tion of NF-κB activation (Figure 6a). Additionally, DHMEQ
reduced the relative SASH1 wild-type and SASH1 mutant
231–1247 nuclear levels (Supplementary Figure 7C). Sub-
cellular fractionation was performed to confirm that DHMEQ
prevents NF-κB P65 binding chromatin following UVC stimuli
(Figure 6b). Furthermore, subcellular fractionation showed
that the inhibition of NF-κB with DHMEQ resulted in an
accumulation of cleaved SASH1 in the cytoplasm, suggesting
that NF-κB activity is required for SASH1 nuclear localisation
(Figure 6c). Next, we examined the expression of apoptotic
genes, which are in part regulated by NF-κB P65. There was a
significant increase in the mRNA expression of antiapoptotic
genes following SASH1 knockdown. In contrast, there was a
significant decrease in the same antiapoptotic genes following
SASH1 overexpression (Supplementary Figure 8). The
proapoptotic gene BAX also showed a decrease following
SASH1 knockdown; however, this did not reach statistical
significance. These data suggest that the induction or
inhibition of apoptosis in SASH1-overexpressing or -depleted
cells, respectively, is through an NF-κB-dependent
mechanism.
Discussion
Apoptosis is a critical cellular process in multicellular organ-
isms enabling the controlled removal of unwanted cells. In
cancer, SASH1 is reported to function as a putative tumour
suppressor. For example, loss of SASH1 is associated with
resistance to apoptosis, while overexpression of SASH1 leads
to an induction of apoptosis.7 However, it remains unclear how
SASH1 functions in apoptotic pathways. In this study, we
examined the role of SASH1 in the activation of apoptosis in
response to UVC radiation. We demonstrated that depletion of
SASH1 prevented apoptosis in cells treated with UVC or
staurosporine. Similar to previous studies,7,13,14 we also
showed that overexpression of SASH1 led to an increase in
apoptotic cells in both HeLa and A549 cell lines. We also
characterised the cleavage of SASH1 and demonstrated that
expression of the C-terminal cleavage fragment including
amino acids 231–1247 was able to induce apoptosis in the
absence of exogenous apoptotic stimuli. We lastly demon-
strated that SASH1-associated apoptosis was driven through
an NF-κB-dependent pathway.
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transfection and were live stained with PI (dead marker) and Hoechst (nuclear
marker). Cells were imaged with an InCell 2200 and apoptotic GFP-positive cells
were quantified. The data shown are the means±S.D. from three independent
experiments. (b) Immunoblot of the chromatin fraction of HeLa cells following UVC
(30 mJ/cm2, 3 h) with or without DHMEQ 10 μg/ml. Confirming DHMEQ inhibits NF-
κB-p65 localisation to the nucleus following UVC stimuli. (c) Immunoblot of the
cytoplasmic fraction of HeLa cells following UVC (30 mJ/cm2, 3 h) treated with or
without DHMEQ (10 μg/ml). Inhibition of NF-κB-p65 induces an accumulation of
SASH1 150 kDa band in the cytoplasm
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Following UVC or staurosporine treatment, a pool of SASH1
was observed to increase at a lower molecular weight.
Interestingly, subcellular fractionation revealed that the
nuclear SASH1 migrated at a lower molecular weight,
suggesting that a cleavage event had occurred. Caspase-3,
-6 and -7 are the three proteases that are responsible for the
proteolysis of proteins for induction of apoptosis.4,31 To identify
the downstream events of apoptosis, it is of fundamental
importance to identify the caspase substrates. Here we have
demonstrated that the apoptosis regulator caspase-3 is
responsible for SASH1 cleavage between amino acids 230
and 231. Many proteins have been shown to be cleaved by
caspases during apoptosis including the multifunctional
protein PARP1 and the human DNA repair nuclease Exo1.32
The cleavage of SASH1 was shown to be required for its
apoptotic role, which indicates it functions downstream to the
initiation of caspase-3 (therefore a modifier of apoptosis);
however, as overexpression of SASH1 increases caspase-9
and initiates apoptosis, it could also function to some degree
as an inducer. Clearly, multiple feedback loops occur within the
apoptotic pathways, which SASH1 appears to be involved
with. The cleavage of nuclear proteins is essential for
apoptosis to proceed, such as the caspase-activated DNase,
which is required for DNA fragmentation. In addition, PARP-1,
a DNA repair-associated protein, is cleaved by caspases
following apoptotic induction, resulting in the formation of both
pro- and antiapoptotic PARP-1 fragments.33,34 Caspase-6 has
been shown to cleave lamins A and C, whereas acinus
cleavage by caspase-3 is required for chromatin
condensation.35,36 Interestingly, cleavage of SASH1 removes
the N-terminal part of SASH1 containing the trypan PARP
domain, thought to be involved in membrane binding. There-
fore, cleavage of SASH1might disrupt its predictedmembrane
interaction aswell as subsequent protein interactions, allowing
its relocation to the nucleus.
We next aimed to determine the mechanism behind the role
of SASH1 in apoptosis. A previous study has suggested that
SASH1 has a role in regulating the transcription factor
NF-κB.28 SASH1 acts as a molecular scaffold to promote the
ubiquitination of TRAF6 (TNF receptor-associated factor 6, E3
ubiquitin-protein ligase) and assemble a complex containing
the NF-κB cofactors TRAF6, TAK1 (transforming growth factor
β-activated kinase 1), IKKa (IκB kinase a) and IKKb, thereby
facilitating activation of NF-κB.28 Of relevance to the current
study, NF-κB also has a role in DNA damage-induced
apoptosis and cells depleted of the p65 NF-κB subunit are,
like SASH1-depleted cells, resistant to UV-induced
apoptosis.21 NF-κB can be observed to translocate to the
nucleus upon induction of apoptosis, where it activates
specific promoters. In light of the above, we next examined
the effect of overexpression of SASH1 on NF-κB activation.
Expression of wild-type and the C-terminal-cleaved fragment
of SASH1 led to an increase in nuclear NF-κB, correlating with
the increased apoptosis in these cells. Expression of the
N-terminal SASH1 fragment or the caspase-3-resistant
SASH1 D230E did not increase the levels of nuclear NF-κB.
This suggests that the C-terminal fragment of SASH1 is
required to promote NF-κB translocation into the nucleus.
Inversely, depletion of SASH1 disrupted the nuclear recruit-
ment of NF-κB following UVC treatment, supporting a role for
SASH1 in NF-κB proapoptotic activation and translocation to
the nucleus.
Interestingly, while we have demonstrated that SASH1 is
required for timely NF-κB activation, the NF-κB inhibitor,
DHMEQ, prevented apoptosis in cells overexpressing SASH1
in a dose-dependent manner, suggesting that the mechanism
of SASH1 induction of apoptosis is, at least in part, through an
NF-κB-dependent pathway. Therefore, we propose that the
C-terminal fragment of SASH1 translocates into the nucleus
and in turn promotes NF-κB proapoptotic roles and reduces
NF-κB antiapoptotic roles. The control of NF-κB translocation
is driven through the degradation of the IKK subunits, and loss
of these IKK subunits results in the activation of NF-κB leading
to nuclear translocation.37 SASH1 is reported to have an
interaction with the IKK subunits α and β either directly or
through a protein complex.28 Therefore, it is possible that
caspase-3-mediated cleavage of SASH1 may act as another
regulatory mechanism to control IKK-mediated translocation
of NF-κB into the nucleus to promote apoptosis.
Recent publications have described SASH1 as having an
inhibitory role on cellular proliferation through the PI3K/Akt
(phosphatidylinositol-4,5-bisphosphate 3-kinase/protein
kinase B) pathways.38,39 SASH1 overexpression was demon-
strated to reduce the phosphorylated PI3K andAkt levelswhile
additionally having effects on epithelial–mesenchymal transi-
tion through the increase of E-cadherin and reduction of
N-cadherin protein levels. The interplay between NF-κB and
PI3K/Akt signalling has previously been described with Akt
being shown to enhance NF-κB activity through the degrada-
tion of IkB.40 The roles of SASH1 within the cellular
proliferation pathways (PI3K/Akt) clearly have implications
on the results described here. It is possible that the effect of
SASH1 on NF-κB levels may be, in part, through its role in the
PI3K/Akt pathway, SASH1 potentially functioning as a
decision point influencing the cells fate leading to cell survival,
proliferation or apoptosis.
SASH1 has been shown to be downregulated in many
cancers.6 These data are highly significant for cancer
treatment as they suggest that cancer cells with low SASH1
levels might be more resistant to DNA damage-induced
apoptosis than cancer cells with higher levels of SASH1. We
have shown here that SASH1 contributes to apoptosis via an
NF-κB-dependent mechanism. Accordingly, drugs that target
NF-κBmight be an effective strategy to target tumours with low
SASH1 levels. Indeed, further investigation is required to
determine if this strategy alone or in combination with DNA-
damaging agents might prove useful in the clinic.
Materials and Methods
Cell culture. Cells were cultured at 37 °C with 5% CO2 in RPMI media and
supplemented with 10% FCS. Cells were passaged with trypsin and maintained at
low passages. Cells were obtained from ATCC (Manassas, USA).
Western blot analysis. Immunoblotting was carried out as described
previously.41 Cells were harvested via scraping in media to retain floating (dead
cells) or trypsinisation from tissue culture plates and were resuspended in
immunoprecipitation (IP) buffer (20 mM HEPES, pH 8, 150 mM KCl, 5% glycerol,
10 mM MgCl2, 0.5% IGEPAL, 0.5 mM EDTA, 0.5 mM dithiothreitol (DTT), protease
inhibitor cocktail (Invitrogen, ThermoFisher Distributer; Brendale QLD, Australia)
(1:100), phosphatase inhibitor cocktail (Invitrogen) (1:100)) and sonicated to lyse the
cells (Vibra Cell, Sonics and Materials, 3 mm probe at amplitude 40 for 10 s).
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Lysates were then centrifuged at 14 000 × g to remove the cellular debris. Samples
(20 μg) were run on Bolt 4–12% gradient gels (165 V for 40–90 min) (Invitrogen)
and proteins were transferred (35 V, 1 h) into a transfer buffer (Tris-Base 25 mM,
glycine 80 mM, 0.15% SDS, 20% methanol) and then to a nitrocellulose membrane
(GE HealthCare Lifesciences, Parramatta NSW, Australia). Membranes were
blocked in 2% fish skin gelatin, 0.1% Tween-20 in PBS (Sigma) (1 h) and incubated
with primary antibody at 4 °C (overnight) in the same buffer. Following washing,
fluorescently labelled secondary antibodies were then incubated with the blot in 2%
fish skin gelatin and 0.1% Tween-20 in PBS (Sigma) (1 h) as indicated. Washed
membranes were visualised using the Li-COR Odyssey infrared scanner (Mulgrave,
VICTORIA, Australia).
SASH1 knockdown. Depletion of SASH1 was performed using Sigma
esiRNA or GenePharma siRNA. Transfections at a final concentration of 20 nM
esiRNA or 50 nM GenePharma siRNA with RNAimax (Life Technologies,
ThermoFisher Distributer; Brendale QLD, Australia) were performed as per the
manufacturer’s instructions. Double transfections were used to achieve optimal
knockdown, where the second transfection was performed 24 h after the initial
round of transfection. Optimal knockdown of SASH1 was observed at 72 h after
initial transfection. GenePharma siRNA sequence 5′-GCAGCAGUAUGC
AGAUUAUTT-3′.
Immunofluorescence microscopy. Immunofluorescence was performed
as described previously.32,42 Briefly, soluble proteins were extracted using extraction
buffer to enrich the chromatin-bound nuclear protein signal (20 mM HEPES (pH 8),
20 mM NaCl, 0.1 mM NaF, 0.5% Igepal) for 5 min, the cells were then fixed with 4%
paraformaldehyde in PBS for 20 min and cells were left in PBS at 4 °C until stained.
For immunostaining, cells were first permeabilised in 0.2% Triton X-100 for 5 min
and then blocked (3% BSA in PBS) for 1 h, followed by incubation with primary
antibodies as indicated. After incubation, cells were washed three times with PBS
before the addition of secondary antibodies as indicated, and these were incubated
for 1 h at room temperature (Alexa Fluro 594 with a 1:400 dilution (Life
Technologies) in 3% BSA). Nuclear DNA was stained with DAPI (Sigma) for 5 min at
1 μg/ml. A Delta Vision Elite Live Imaging Microscope (Applied Precision, GE
HealthCare Lifesciences, Parramatta NSW, Australia) and softWoRx analysis
software (Applied Precision) were used for the cell imaging. High-throughput
analysis was performed using a Incell 2200 (GE Healthcare Lifesciences,
Parramatta NSW, Australia) and a Incell investigator analysis software (GE
Healthcare).
SASH1 transduction. Myc-tagged SASH1 constructs were cloned into pLEX
307 via a LR reaction. HEK293T virus-producing cells were cultured in DMEM
containing 10% FCS at low passage. A T75 flask of cells was transfected with virus
component plasmids (15 μg of pLP1, 6 μg of pLP2, 3 μg of pVSV-G) with
Lipofectamine 2000 (ThermoFisher; Brendale QLD, Australia). Virus containing
media were collected 24 and 48 h after transfection. Cellular debris was removed by
centrifugation at 600 × g for 10 min. Virus was used fresh or stored at − 80 °C.
Transduction of HeLa cells was performed by the addition of virus-containing medium
to cells. Polybrene 1:6000 (Sigma-Aldrich) was used to increase transduction
efficiency, with a second transduction performed 6 h after the first transduction. Cells
were left 48 h after initial transduction before being harvested for experiments.
SASH1 fragment overexpression was assessed by western blot analysis.
SASH1 overexpression. The SASH1 gene was cloned into a mammalian
expression vector PCMV6 (Origene, Dianostic Technology; Belrose NSW,
Australia). For a T25 flask, 3 μg of DNA and 6 μl of Lipofectamine 2000 was
used, with DNA and Lipofectamine incubated separately for 5 min and then
combined and allowed to incubate for 20 min before being added to the cells as per
the manufacturer's instructions. Cells were harvested 24–48 h after transfection.
Annexin V/PI analysis. HeLa or A549 cells transduced with SASH1, were
trypsinised and stained as per the instructions of Promega Annexin V-FITC
Apoptosis Detection Kit (United Bioresearch; Dural NSW, Australia). Cells were
resuspended to 1 × 106–2 × 106 cells per ml in a 1 × binding buffer with 1 : 40
dilution of 488-Annexin antibody and then incubated for 20 min in the dark. Cells
were washed in a 1 × binding buffer and then resuspended in 1 × binding buffer
containing 1 : 20 dilution of propidium iodide (PI). Fluorescence of cells was
measured using the Gallios flow cytometer system and was analysed using the
Kaluza software (Beckman, Lane Cove NSW, Australia).
N-terminal sequencing. Ectopically expressed SASH1 was immunoprecipi-
tated from 4 × T175 flasks. The immunoprecipitation sample was then electro-
phoresed into a Bolt gel 4–12% (Invitrogen) and immunoblotted onto the PVDF
membrane. The membrane was then stained with Coomassie R250 to visualise
SASH1. The band representing the smaller cleaved fragment of SASH1 was
excised from the blot using a sterile scalpel and sent to APAF for N-terminal
sequencing with six rounds of Edman degradation.
UVC and staurosporine-induced apoptosis. Cells were seeded into
10 cm dishes, allowed to attach overnight and exposed to indicated doses of UVC
using a UVC crosslinker (Syngene GCL8S Crosslinker UV Radiation System
Cleaver Scientific; Rugby, Warwickshire, UK used with a 254 nM wavelength) or
treated with 1 μM staurosporine. Live as well as necrotic and apoptotic floating cells
were harvested following indicated time points.
Subcellular fractionation. This was performed using the Thermo Scientific
Subcellular Fractionation Kit (ThermoFisher; Brendale QLD, Australia), through a
stepwise lysis and centrifugation of cells into functional cytoplasmic-, membrane-,
nuclear-soluble, chromatin-bound and cytoskeleton protein fractions as per the
manufacturer's instructions.
NF-κB inhibitor DHMEQ. The NF-κB inhibitor DHMEQ from Kazuo
Umezawa (Aichi Medical University, Nagakute, Japan) was added to cells 6 h
following SASH1-GFP transfected in 96-well plates (200 ng DNA, 0.5 μl Fugene HD
per well). DHMEQ was added to the cells at 0, 1, 2, 5, 10, 20 or 50 μg/ml. Cells
were treated with DHMEQ for 48 h before cell death was assessed using Incell
2200 imaging and was analysed using Incell analysis software (GE HealthCare
Lifesciences, Parramatta NSW, Australia), in combination with PI and Hoechst
staining.
Caspase inhibitor Z-VAD-FMK. Stably expressing ectopic SASH1-Flag
U2OS cells were treated with UVC to induce cell death with the addition of
Z-VAD-FMK (50 μM) to inhibit caspase activity. Lysates were immunoprecipitated
(1 mg) with M2-Flag beads (20 μl) and SASH1 was eluted from the beads with
2 × SDS loading dye with 5% β-mercaptoethanol.
Recombinant caspase-3 cleavage. SASH1 was immunoprecipitated from
U2OS cells stably expressing ectopic SASH1. Beads were washed five times in IP
buffer to remove contaminating proteins. SASH1-bound beads were incubated for
16 h in protease inhibitor-free buffer (25 mM HEPES, 0.1% (w/v) CHAPS, 10 mM
DTT, pH 7.5) with and without 2 U of active recombinant caspase-3 (Abcam,
Melbourne, VIC, Australia). SASH1 was then eluted from the beads with 2 × SDS
loading dye containing 5% β-mercaptoethanol.
Quantitative real-time PCR. Quantitative real-time PCR (qRT-PCR) was
performed as described previously.43 In summary, 1 μl diluted cDNA reverse
transcribed from total RNA in nuclease-free H2O (1 : 5), 50 nM forward and reverse
primer, 1x final concentration of SYBR Green PCR Master Mix (Applied Biosystems,
ThermoFisher; Brendale QLD, Australia) and nuclease-free H2O (total volume of
10 μl). Reactions were performed using a ViiA7 Real-Time PCR System (Life
Technologies). Cycling conditions were 95 °C for 10 min, 40 cycles of 95 °C for 15 s
and 60 °C for 1 min followed by a primer-template dissociation step. Gene
expression was normalised to 7SL mRNA levels using the comparative CT (CT)
method. The primer sequences for the human genes are given in Supplementary
Table S1.
Statistical analysis. Statistics analysis was performed using the GraphPad
Prism analysis software (La Jolla, CA, USA). Student's T-test were performed with
P-values as indicated, *Po0.05, **Po0.005 and ***Po0.0005.
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